• Success of MSC Development Target triggers Milestone Payment
    Alastair Smith

News

Success of MSC Development Target triggers Milestone Payment

Life sciences company Avacta has announced a second milestone equity payment increasing its shareholding in AffyXell Therapeutics, a joint venture to develop next-generation cell therapies between Avacta and Daewoong Pharmaceutical in South Korea.

Following successful development and characterisation of Affimer® proteins against the second target of interest for AffyXell, application to file a patent for the associated intellectual property triggered the second milestone. The exact increase in the shareholding will be determined, as with the first milestone payment, following a formal valuation of the joint company.

Established in January 2020, AffyXell develops novel mesenchymal stem cell ("MSC") therapies. 

Dr Alastair Smith, Chief Executive Officer of Avacta Group, said: “We are delighted that such rapid progress has been made with the second target in our joint venture in South Korea. There is great potential for AffyXell’s novel, engineered mesenchymal stem cell platform incorporating Avacta’s Affimer® technology to deliver significant improvements to the standard of care for patients with serious diseases.

“We continue to work closely with our colleagues at AffyXell and Daewoong to advance this cutting edge therapeutic platform.”

More information online


Digital Edition

ILM Guide 2025/26

June 2025

Buyers' Guide Listings- Product Listings by Category- Suppliers Listings (A-Z)Chromatography Articles- Setting the power coefficient and the baseline to linearise the signal of the evaporative ligh...

View all digital editions

Events

AUTOMATICON

Jun 24 2025 Warsaw, Poland

CPhI & P-MEC China 2025

Jun 24 2025 Shanghai, China

Discovery & Development Europe 2025

Jul 01 2025 Basel, Switzerland

MMC 2025

Jul 01 2025 Manchester, UK

analytica Lab Africa

Jul 08 2025 Johannesburg, South Africa

View all events